A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS)

Toxins

Volumn 4, Issue 11, 2012, Pages 1309-1322

  Akiyama, Yasutoshi ^a   Takeuchi, Yoichi ^a   Kikuchi, Koichi ^a   Mishima, Eikan ^a   Yamamoto, Yasuaki ^a   Suzuki, Chitose ^a   Toyohara, Takafumi ^a   Suzuki, Takehiro ^a   Hozawa, Atsushi ^b   Ito, Sadayoshi ^a   Soga, Tomoyoshi ^c   Abe, Takaaki ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c KEIO UNIVERSITY   (Japan)

Author keywords

AST 120; CE MS; Uremic toxin

Indexed keywords

4 GUANIDINOBUTYRIC ACID; 5 METHYLCYTOSINE; ALLANTOIN; ANION; AST 120; CATION; CYTOSINE; GLYCINE; HIPPURIC ACID; IMIDAZOLE; INDICAN; LEVULINIC ACID; N ACETYLNEURAMINIC ACID DERIVATIVE; PYRIDOXIC ACID; THEANINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG BLOOD LEVEL; ELECTROSPRAY MASS SPECTROMETRY; IN VIVO STUDY; MASS SPECTROMETRY; METABOLOMICS; NEPHRECTOMY; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SYSTOLIC BLOOD PRESSURE;

ADMINISTRATION, ORAL; ADSORPTION; ANIMALS; ANIONS; CARBON; CATIONS; DISEASE MODELS, ANIMAL; ELECTROPHORESIS, CAPILLARY; KIDNEY FUNCTION TESTS; MASS SPECTROMETRY; METABOLOME; METABOLOMICS; NEPHRECTOMY; OXIDES; RATS; RATS, WISTAR; RENAL INSUFFICIENCY, CHRONIC; TOXINS, BIOLOGICAL; UREMIA;

RATTUS;

EID: 84870563668     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins4111309     Document Type: Article

References (26)

1. Levey, A.S.; Coresh, J. Chronic kidney disease. Lancet 2012, 379, 165-180.
2. Go, A.S.; Chertow, G.M.; Fan, D.; McCulloch, C.E.; Hsu, C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N. Engl. J. Med. 2004, 351, 1296-1305.
3. Watanabe, H.; Miyamoto, Y.; Otagiri, M.; Maruyama, T. Update on the pharmacokinetics and redox properties of protein-bound uremic toxins. J. Pharm. Sci. 2011, 100, 3682-3695.
4. Vanholder, R.; Glorieux, G.; De Smet, R.; Lameire, N. New insights in uremic toxins. Kidney Int. 2003, 63 (Suppl. 84), S6-S10.
5. Vanholder, R.; Baurmeister, U.; Brunet, P.; Cohen, G.; Glorieux, G.; Jankowski, J. A bench to bedside view of uremic toxins. J. Am. Soc. Nephrol. 2008, 19, 863-870.
6. Niwa, T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: Experimental and clinical effects of oral sorbent AST-120. Ther. Apher. Dial. 2011, 15, 120-124.
7. Goto, S.; Yoshiya, K.; Kita, T.; Fujii, H.; Fukagawa, M. Uremic toxins and oral adsorbents. Ther. Apher. Dial. 2011, 15, 132-134.
8. Niwa, T.; Miyazaki, T.; Hashimoto, N.; Hayashi, H.; Ise, M.; Uehara, Y.; Maeda, K. Suppressed serum and urine levels of indoxyl sulfate by oral sorbent in experimental uremic rats. Am. J. Nephrol. 1992, 12, 201-206.
9. Kikuchi, K.; Itoh, Y.; Tateoka, R.; Ezawa, A.; Murakami, K.; Niwa, T. Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J. Chromatogr. B 2010, 878, 2997-3002.
10. Ueda, S.; Yamagishi, S.; Takeuchi, M.; Kohno, K.; Shibata, R.; Matsumoto, Y.; Kaneyuki, U.; Fujimura, T.; Hayashida, A.; Okuda, S. Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure. Mol. Med. 2006, 12, 180-184.
11. Toyohara, T.; Suzuki, T.; Morimoto, R.; Akiyama, Y.; Souma, T.; Shiwaku, H.O.; Takeuchi, Y.; Mishima, E.; Abe, M.; Tanemoto, M.; et al. SLCO4C1 transporter eliminates uremic toxins and attenuates hypertension and renal inflammation. J. Am. Soc. Nephrol. 2009, 20, 2546-2555.
12. Toyohara, T.; Suzuki, T.; Akiyama, Y.; Yoshihara, D.; Takeuchi, Y.; Mishima, E.; Kikuchi, K.; Suzuki, C.; Tanemoto, M.; Ito, S.; et al. Metabolomic profiling of the autosomal dominant polycystic kidney disease rat model. Clin. Exp. Nephrol. 2011, 15, 676-687.
13. Toyohara, T.; Akiyama, Y.; Suzuki, T.; Takeuchi, Y.; Mishima, E.; Tanemoto, M.; Momose, A.; Toki, N.; Sato, H.; Nakayama, M.; et al. Metabolomic profiling of uremic solutes in CKD patients. Hypertens. Res. 2010, 33, 944-952.
14. Soga, T.; Ohashi, Y.; Ueno, Y.; Naraoka, H.; Tomita, M.; Nishioka, T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J. Proteome Res. 2003, 2, 488-494.
15. Soga, T.; Heiger, D.N. Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry. Anal. Chem. 2000, 72, 1236-1241.
16. Soga, T.; Igarashi, K.; Ito, C.; Mizobuchi, K.; Zimmermann, H.P.; Tomita, M. Metabolomic profiling of anionic metabolites by capillary electrophoresis mass spectrometry. Anal. Chem. 2009, 81, 6165-6174.
17. Soga, T.; Ueno, Y.; Naraoka, H.; Ohashi, Y.; Tomita, M.; Nishioka, T. Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry. Anal. Chem. 2002, 74, 2233-2239.
18. Soga, T.; Baran, R.; Suematsu, M.; Ueno, Y.; Ikeda, S.; Sakurakawa, T.; Kakazu, Y.; Ishikawa, T.; Robert, M.; Nishioka, T.; Tomita, M. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol. Chem. 2006, 281, 16768-16776.
19. Vanholder, R.; Van Laecke, S.; Glorieux, G. What is new in uremic toxicity? Pediatr. Nephrol. 2008, 23, 1211-1221.
20. Kand'ar, R.; Zakova, P. Allantoin as a marker of oxidative stress in human erythrocytes. Clin. Chem. Lab. Med. 2008, 46, 1270-1274.
21. Biedron, R.; Ciszek, M.; Tokarczyk, M.; Bobek, M.; Kurnyta, M.; Slominska, E.M.; Smolenski, R.T.; Marcinkiewicz, J. 1-Methylnicotinamide and nicotinamide: Two related anti-inflammatory agents that differentially affect the functions of activated macrophages. Arch. Immunol. Ther. Exp. (Warsz.) 2008, 56, 127-134.
22. Chlopicki, S.; Swies, J.; Mogielnicki, A.; Buczko, W.; Bartus, M.; Lomnicka, M.; Adamus, J.; Gebicki, J. 1-Methylnicotinamide (MNA), a primary metabolite of nicotinamide, exerts anti-thrombotic activity mediated by a cyclooxygenase-2/prostacyclin pathway. Br. J. Pharmacol. 2007, 152, 230-239.
23. Watala, C.; Kazmierczak, P.; Dobaczewski, M.; Przygodzki, T.; Bartus, M.; Lomnicka, M.; Slominska, E.M.; Durackova, Z.; Chlopicki, S. Anti-diabetic effects of 1-methylnicotinamide (MNA) in streptozocin-induced diabetes in rats. Pharmacol. Rep. 2009, 61, 86-98.
24. Swendseid, M.E.; Wang, M.; Vyhmeister, I.; Chan, W.; Siassi, F.; Tam, C.F.; Kopple, J.D. Amino acid metabolism in the chronically uremic rat. Clin. Nephrol. 1975, 3, 240-246.
25. Bain, M.A.; Faull, R.; Fornasini, G.; Milne, R.W.; Evans, A.M. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol. Dial. Transplant. 2006, 21, 1300-1304.
26. Wang, Z.; Klipfell, E.; Bennett, B.J.; Koeth, R.; Levison, B.S.; Dugar, B.; Feldstein, A.E.; Britt, E.B.; Fu, X.; Chung, Y.M.; et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011, 472, 57-63.